Psych HealthPGx Panel
CYP2C19 Rapid Genotyping
Actionable Pharmacogenomics Testing for all ethnicities
How Inclusive Pharmacogenomics Improves Care for Every Patient
Effectiveness and safety of drug treatments varies significantly from one individual to another. Adjusting prescriptions to account for these differences has often required trial-and-error, placing the patient at risk for an adverse drug reactions (ADRs) or ineffective treatment. Scientific breakthroughs in the field of Pharmacogenomics (PGx) have uncovered the associations between individual’s genetic profiles and response to certain drugs.
Leveraging our scientific team’s 20+ years of genomics research and scientific breakthroughs, RPRD develops and offers inclusive PGx testing, to enable personalize therapies, improving clinical outcomes for every patient across all races and ethnicities.
Why Partner with RPRD?
The most comprehensive PGx testing
Our flagship Whole Pharmacogenomics Scan (WPS®) is the most comprehensive, customizable, and scalable clinical PGx test. WPS® creates a complete PGx profile that can potentially meet a patient’s life-long PGx needs.
Pan-ethnic Pharmacogenomics
Our philosophy is to build on status-quo testing of common genetic alleles with new approaches to assess genetic alleles that are rare or known to specific race/ethnicity. This enables us to advance the field with next generation clinical PGx tests that are comprehensive, inclusive, and trusted.
Leading PGx research and clinical implementations
Building upon our 20+ years of experience in genomics research and 110+ peer-reviewed publications, our team collaborates with the leaders in genomic medicine including St Jude Children’s Research Hospital and Harvard Medical School, and advance PGx clinical implementations by actively contributing to the PGx communities, such as CDC’s GeT-RM program, PharmVar and PGx Global Research Network.
EMPOWER PERSONALIZED CARE
End-to-end solutions to enable precision medicine
We leverage advanced technologies and our decades-long experience in genetics research to bring pharmacogenetics into the mainstream. We empower clinicians with complete solutions, so they can focus on providing better care for their patients.
Evidence-based high-quality solutions
Our PGx solutions are formulated based on the latest clinical practice guidelines, which are supported by rigorous peer-reviewed clinical and scientific evidence.
ACCELERATE PERSONALIZED THERAPIES
Our drug development partners trust our academic excellence and decades of scientific research experience in genetics and the impact of genetics on drug responses. Through our continued research in modern technologies and drug R&D, we help our partners pursue personalized therapies to achieve better care for tomorrow.
Latest Insights
Webinar Recording: Impact of CYP2D6 PGx
CYP2D6 is an important pharmacogenetics (PGx) gene as it is involved in the metablism of ~25% of clinically prescribed drugs. Dr. Cyrine-Eliana Haidar at St Jude Children’s Research Hospital will discuss how to use CYP2D6 genetic information to guide drug dosing and improve patient care.
Webinar Recording: PGx for Minorities
Health disparities exist among various ethnicity groups in the United States. Together with multiple social-economic factors, genetic variations contribute to the variability across the populations. Most of the genomics and PGx studies have been conducted mainly on population of European descent. The presentation will review current approaches for PGx testing, latest scientific evidence and infrastructure needs for better addressing the issue.
Podcast: the Voice of Healthcare
Dr. Hyun Kim, Clinical Pharmacist with Boston Children’s Clinical Pharmacogenomics Service and Dr. Ulrich (Uli) Broeckel, Founder and CEO of RPRD explore pharmacogenetics and precision medicine, the application to clinical medicine and decision making, and most importantly, the benefits to patients and clinical teams.
Understanding the relationship between an individual’s genetic profile and their pharmacokinetics is very important to our clinical studies. RPRD’s breadth of experience with comprehensive PGx-profiling tests and in-depth data analysis is exactly what we were looking for. I would highly recommend their services.
Unlock the power of science
RPRD is accelerating personalized therapies of tomorrow through its long-term commitment to advancing PGx with scientific breakthroughs and innovations.
PGx Diagnostic Solutions
RPRD’s experience in precision medicine and its CLIA-certified laboratory offer a wide range of PGx diagnostic services to meet your unique needs.
References
- Spear BB, et al. Clinical Application of Pharmacogenetics. Trends Mol. Med. 2001 May;7(5):201-4.
- FDA “Preventable Adverse Drug Reactions.” 2018.
- Relling MV, et al. Pharmacogenomics in the Clinic. Nature. 2015 Oct;526(7573):343-50.
- Ji Y, et al. Preemptive Pharmacogenomic Testing for Precision Medicine: A Comprehensive Analysis of Five Actionable Pharmacogenomic Genes Using Next-Generation DNA Sequencing and a Customized CYP2D6 Genotyping Cascade. J Mol. Diagn. 2016 May;18(3):438-46.
- Dunnenberger HM, et al. Preemptive Clinical Pharmacogenetics Implementation: Current Programs in Five US Medical Centers. Annu Rev Pharmacol Toxicol. 2015 Jan;55:89-106.